安罗替尼联合NP方案化疗对晚期非小细胞肺癌患者的疗效观察

Effect of Anrotinib Combined with NP Regimen Chemotherapy on Patients with Advanced Non-Small Cell Lung Cancer

目的:分析安罗替尼联合NP方案治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效。方法:选取联勤保障部队第983医院2019年9月至2020年9月收治的80例晚期NSCLC患者,根据不同治疗方案分为观察组、对照组,各40例。两组均给予常规干预,对照组采用NP方案化疗,观察组在上述基础上采用安罗替尼治疗。比较两组患者疾病控制率、治疗前后卡氏行为状态(KPS)评分、胸腔积液肿瘤标志物〔糖类抗原199(CA)、糖类抗原125(CA125)、癌胚抗原(CEA)〕水平、胸腔积液血管内皮生长因子(VEGF)水平及不良反应发生率。结果:观察组患者疾病控制率为97.50 %,高于对照组的75.00 %,差异具有统计学意义(P<0.05);治疗1周后、3周后,观察组患者KPS评分均较对照组更高,差异具有统计学意义(P<0.05);治疗1周、3周后观察组患者胸腔积液VEGF水平均较对照组更低,差异具有统计学意义(P<0.05);治疗3周后,观察组患者CEA、CA199、CA125水平均低于对照组,差异具有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:NSCLC患者采用安罗替尼联合NP方案疗效确切,可有效改善患者生存质量,抑制肿瘤标志物、胸腔积液VEGF水平,且具有较高的用药安全性。

Objective To analyze the clinical efficacy of anrotinib combined with NP regimen in the treatment of advanced non-small cell lung cancer (NSCLC).Methods A total of 80 patients with advanced NSCLC admitted to the 983th Hospital of Joint Logistic Support Force from September 2019 to September 2020 were selected and divided into observation group and control group according to different treatment regimens,with 40 cases in each group.Both groups were given routine intervention,the control group was treated with NP chemotherapy,and the observation group was treated with antirotinib on the above basis.Disease control rate,KPS score,pleural effusion tumor marker level,pleural effusion vascular endothelial growth factor (VEGF) level and incidence of adverse reactions were compared between two groups before and after treatment.Results The disease control rate in the observation group was 97.50%,higher than 75.00% in the control group,the difference was statistically significant (P < 0.05).After 1 week and 3 weeks of treatment,KPS score of the observation group was higher than that of the control group,the difference was statistically significant (P < 0.05).After 1 and 3 weeks of treatment,the level of VEGF in pleural effusion in the observation group was lower than that in the control group,and the difference was statistically significant (P < 0.05).After 3 weeks of treatment,CEA,CA199 and CA125 levels in the observation group were lower than those in the control group,the differences were statistically significant (P < 0.05).There was no significant difference in the incidence of adverse reactions between two groups (P > 0.05).Conclusion Anluotinib combined with NP regimen has a definite efficacy for NSCLC patients,which can effectively improve patients’ quality of life,inhibit tumor markers and VEGF levels in pleural effusion,and has a high medication safety.